Bliss GVS Pharma Unit Gets MHRA Authorization for Mesalazine Suppositories
A Bliss GVS Pharma unit obtained marketing authorization from the UK’s MHRA for mesalazine 1g suppositories.
Related stories
Jiangsu Leili Motor Says Controller Su Da Is Under Regulatory Investigation
Jiangsu Leili Motor says its actual controller Su Da is under investigation by China’s securities regulator over suspected information-disclosure and share-reduction violations.
L impact | REGULATION | Nov 04, 2026, 11:41 AM UTC
India Accuses PepsiCo and Monster of Misleading Energy-Drink Marketing
India accuses PepsiCo and Monster of marketing their products as “energy drinks” to mislead consumers.
M impact | REGULATION | Nov 04, 2026, 11:39 AM UTC
India Regulator Accuses PepsiCo, Monster Over Energy Drink Labels
India's food regulator accused the companies of marketing high-caffeine beverages as energy drinks to mislead consumers, according to court filings reviewed by Reuters. The case ma
L impact | REGULATION | Nov 04, 2026, 11:37 AM UTC
India Supreme Court Upholds States’ Pre-GST Power to Levy Additional Tax
A seven-judge Constitution Bench reaffirmed states’ authority to impose an additional tax, surcharge or cess calculated on an existing sales tax, resolving a legal question that ha
M impact | REGULATION | Nov 04, 2026, 11:36 AM UTC
Democrats Win Both Houses of Congress in US Midterms
Democrats took control of both houses of Congress in a midterm election result described as a referendum on Donald Trump's agenda.
M impact | REGULATION | Nov 04, 2026, 11:33 AM UTC
Planet 13 Receives DEA Registrations for 34 Florida Dispensaries
L impact | REGULATION | Nov 04, 2026, 11:33 AM UTC